Mandate

Vinge advises Bygghemma in connection with acquisition of Hemfint

February 26, 2020

Vinge has advised Bygghemma Sverige AB in connection with the acquisition of 84 per cent of the shares in Hemfint Kristianstad AB for a fixed purchase price regarding 51 per cent of the shares, an earn-out based purchase price regarding 33 per cent of the shares over a 3-year period as well as an option to acquire the remaining shares within 3-4 years.

Bygghemma is the leading online based European supplier of products and services within DIY and home furnishings. In 2019, Bygghemma’s turnover was SEK 6.2 billion and the company employs more than 1 500 persons, has its head office in Malmö and is listed on Nasdaq Stockholm, Mid Cap. Hemfint is a fast-growing online provider of doors, windows, bathroom and leisure products in Sweden under its own trademarks and had a turnover of more than SEK 150 million in 2018.

Vinge’s team consisted of partner Kristian Ford together with, among others, associates Niklas Törnell, Tilda Hall, Jessica Salomonsson (commercial property/real estate) and Freja Najafi Kristensen (employment). 

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026